NCT00715702View on ClinicalTrials.gov

Safety Study of AZD5672 in Renally Impaired Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Renal Impairment

Interventions

DRUG

AZD5672

100 mg oral single dose

Trial Locations (1)

Unknown

Research Site, München

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY